Arrowroot Family Office’s Amgen AMGN Stock Holding History

Arrowroot Family Office’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-923	Closed	-$205K	–	117
2023 Q2	$205K	Buy	+923	New	+$214K	0.16%	119

Other funds holding AMGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Arrowroot Family Office's AMGN Position: Q3 2023 in Review

Arrowroot Family Office sold out of Amgen (AMGN) in Q3 2023, closing a stake of 923 shares — an estimated $205K sold.

Arrowroot Family Office first reported a position in AMGN in Q2 2023 and held it in 1 quarter. The position peaked at $205K in Q2 2023. 2,502 funds tracked by Wall St. Rank hold AMGN as of Q3 2023.

Arrowroot Family Office reported no remaining Amgen position as of Q3 2023 after selling out during the quarter.
Arrowroot Family Office sold 923 Amgen shares in Q3 2023, an estimated $205K.
Arrowroot Family Office first reported a position in Amgen in Q2 2023 and held it in 1 quarter.
Arrowroot Family Office's Amgen position peaked at $205K in Q2 2023.
2,502 funds tracked by Wall St. Rank held Amgen as of Q3 2023.

Based on Arrowroot Family Office's 13F filing for Q3 2023, filed 17 Apr 2024.